Arcus Biosciences, Inc. (RCUS)
$22.51-7.52%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.8B
- Beta
- 0.81
- P/E (TTM)
- -5.73
- Short % float
- 15.81%
- Days to cover
- 7.6
- SI change
- -5.1%
- 1W
- -7.29%
- 1M
- -6.48%
- vs SPY 1W
- -7.15%
- vs SPY 1M
- -8.99%
Industry peers
FMP comparable companies · ranked by market cap
- IBRXBUYImmunityBio, Inc.$11.0BRECOVERYQ 8$10.51-3.16%
- COGTSELLCogent Biosciences, Inc.$5.3BCRISISQ 12$31.00-5.67%
- DNLISELLDenali Therapeutics Inc.$3.1BCRISISQ 8$19.45-2.90%
- BEAMBUYBeam Therapeutics Inc.$2.6BRECOVERYQ 13$25.70-2.79%
- LQDASELLLiquidia Corporation$2.4BCRISISQ 12$27.38-3.11%
- ETNB89bio, Inc.$2.2B$14.84
- VRDNSELLViridian Therapeutics, Inc.$2.1BCRISISQ -3$18.66-0.44%
- AGIOSELLAgios Pharmaceuticals, Inc.$1.9BRECOVERYQ 4$31.81-1.98%
- GLPGGalapagos N.V.$1.8B$27.98
- OCULSELLOcular Therapeutix, Inc.$1.7BCRISISQ 3$7.54-4.23%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RCUS?
- LOPJLB’s latest quantitative signal on Arcus Biosciences, Inc. (RCUS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RCUS in?
- Arcus Biosciences, Inc. (RCUS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Arcus Biosciences, Inc. (RCUS) do?
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The companyâs development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelima…